X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$0.70 USD
0.00 (0.06%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.70 0.00 (-0.46%) 6:28 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for X4 Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 3 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 3 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 108 | 88 | 85 | 63 | 52 |
Income After Depreciation & Amortization | -108 | -88 | -85 | -60 | -52 |
Non-Operating Income | 12 | -2 | 0 | 1 | 1 |
Interest Expense | 6 | 4 | 4 | 3 | 2 |
Pretax Income | -101 | -94 | -89 | -62 | -53 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -101 | -94 | -89 | -62 | -53 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -101 | -94 | -89 | -62 | -53 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -107 | -87 | -75 | -60 | -52 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 10 | 0 | 0 |
Income After Depreciation & Amortization | -108 | -88 | -85 | -60 | -52 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 177.81 | 63.53 | 25.75 | 20.08 | 11.53 |
Diluted EPS Before Non-Recurring Items | -0.57 | -1.52 | -3.99 | -3.09 | -4.63 |
Diluted Net EPS (GAAP) | -0.57 | -1.52 | -3.99 | -3.09 | -4.63 |
Fiscal Year end for X4 Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.56 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | -70.81 | 37.29 | 25.20 | 27.21 | 25.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | 71.11 | -37.29 | -25.20 | -27.21 | -25.80 |
Non-Operating Income | 21.92 | -12.58 | 7.99 | 26.57 | -28.74 |
Interest Expense | 2.18 | 1.87 | 1.89 | 1.63 | 1.15 |
Pretax Income | 90.85 | -51.75 | -19.10 | -2.28 | -55.70 |
Income Taxes | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 90.83 | -51.77 | -19.13 | -2.31 | -55.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 90.83 | -51.77 | -19.13 | -2.31 | -55.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 200.80 | 199.99 | 198.77 | 196.99 | 168.74 |
Diluted EPS Before Non-Recurring Items | -0.07 | -0.26 | -0.10 | -0.01 | -0.33 |
Diluted Net EPS (GAAP) | 0.45 | -0.26 | -0.07 | -0.01 | -0.33 |